DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) shares crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.91 and traded as high as $4.46. DBV Technologies shares last traded at $4.39, with a volume of 6,288 shares.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on DBVT shares. JMP Securities restated a "market outperform" rating and set a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th. StockNews.com started coverage on shares of DBV Technologies in a research report on Tuesday. They set a "hold" rating on the stock. Finally, HC Wainwright raised their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th.
Check Out Our Latest Stock Report on DBV Technologies
DBV Technologies Trading Up 3.1 %
The company has a market capitalization of $90.30 million, a price-to-earnings ratio of -0.98 and a beta of 0.67. The firm's 50 day simple moving average is $3.98 and its 200-day simple moving average is $3.85.
Hedge Funds Weigh In On DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 71.74% of the company's stock.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
See Also
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
